Blood Thinner May Slow Cognitive Decline in Alzheimer’s Patients With AFib
Recent research from Sweden has revealed promising results regarding the use of newer blood thinners, known as non-vitamin K antagonist oral anticoagulants (NOACs), in slowing cognitive decline for individuals suffering from both atrial fibrillation (AFib) and Alzheimer’s disease. The study suggests that these medications not only help decrease the risk of strokes but may also contribute positively to brain health.
Alzheimer’s patients with AFib are particularly vulnerable to “silent strokes,” which can cause significant brain damage over time. NOACs work by preventing blood clots that can lead to these strokes, thereby potentially reducing cognitive deterioration. According to Maria Eriksdotter, a leading researcher from the Karolinska Institute in Stockholm, the treatment may enhance blood flow and diminish minor brain damage, leading to cognitive benefits.
The study, published in the *European Heart Journal*, analyzed data from over 7,300 Alzheimer’s patients with AFib. Researchers tracked cognitive function using the Mini-Mental State Examination (MMSE), a standard test that measures various cognitive abilities, along with other health data from Swedish national registries. Participants were divided into three groups: those not on blood thinners, those taking warfarin (an older blood thinner), and those using NOACs.
Results indicated that participants using NOACs experienced a slower rate of cognitive decline compared to those on warfarin or those not receiving any anticoagulant treatment. While warfarin users did not show any notable differences in memory loss compared to non-users, NOAC users demonstrated a significant slowing of cognitive decline. Additionally, NOAC users enjoyed lower risks of stroke, death, and fractures without a corresponding increase in major bleeding incidents, which is a common concern associated with blood thinners.
The findings are particularly noteworthy because managing warfarin can be challenging, particularly for individuals with cognitive impairments. In contrast, NOACs are easier to administer and do not require constant monitoring, making them a safer option for patients who may struggle with adherence to treatment protocols.
The implications of this research could reshape how healthcare providers approach treatment for patients with both AFib and Alzheimer’s. Bhaskar Semitha, a cardiothoracic surgeon not involved in the study, emphasized that NOACs could alter the risk-benefit analysis concerning blood thinners for elderly patients. Traditionally, doctors may have been hesitant to prescribe such medications due to concerns over severe bleeding risks. However, with evidence suggesting cognitive benefits and a reduced risk of complications from NOACs, physicians may begin to see these drugs as dual-purpose treatments that protect brain health as well as cardiovascular health.
As medical professionals increasingly collaborate between cardiovascular and neurological specialties, NOACs may become recognized not just as tools for stroke prevention but as potentially neuroprotective therapies that can help slow the progression of Alzheimer’s disease.
